Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition

M. Matsui, R. J. Moots, R. J. Warburton, A. L. Peace-Brewer, L. G. Tussey, D. G. Quinn, A. J. McMichael, Jeffrey A Frelinger

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

During the course of extensive mutagenesis of HLA-A2.1, we examined influenza A matrix peptide (FMP)-specific CTL recognition of HMy2.C1R (C1R) cells expressing mutant HLA-A2.1 molecules, sensitized with synthetic peptide, FMP 58-66, (exogenous peptide), or infected with influenza A virus (endogenous peptide). Most mutants showed equivalent presentation of exogenous and endogenous peptides to FMP-specific CTL. However, five of the mutants differed in this property. Two of the five mutants, F9L and T134K, present exogenous peptide to FMP-specific CTL, but fail to present endogenous peptide to CTL. Western blot analysis using anti-matrix protein Ab indicates that the matrix protein is expressed in these mutants after infection with virus. Interestingly, transfection of these two mutants with a minigene encoding FMP 58-66 results in efficient lysis by FMP-specific CTL. Peptide- binding assays demonstrate that the two mutations dramatically decrease the binding of FMP. However, these mutants bind FMP as well as wild type in the presence of exogenously added human β2-m, suggesting that the lower affinity for β2-m leads to the inability to present endogenous peptide. The remaining three mutants, Y27N, Q32K, and S132C, fail to present exogenous peptide, but present endogenous peptide to FMP-specific CTL. Pulse-chase analyses followed by endoglycosidase-H treatment show that the rate of maturation and processing of the five mutant HLA-A2 molecules in C1R cells is identical to that of wild type. Overall, this study suggests that the assembly and subsequent recognition of endogenous peptide differs from that of exogenous peptide.

Original languageEnglish (US)
Pages (from-to)1088-1096
Number of pages9
JournalJournal of Immunology
Volume154
Issue number3
StatePublished - 1995
Externally publishedYes

Fingerprint

Human Influenza
Peptides
HLA-A2 Antigen
N-formylmethionylphenylalanine
Glycoside Hydrolases
Influenza A virus
Virus Diseases
Mutagenesis
Transfection
Proteins
Western Blotting
Mutation

ASJC Scopus subject areas

  • Immunology

Cite this

Matsui, M., Moots, R. J., Warburton, R. J., Peace-Brewer, A. L., Tussey, L. G., Quinn, D. G., ... Frelinger, J. A. (1995). Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition. Journal of Immunology, 154(3), 1088-1096.

Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition. / Matsui, M.; Moots, R. J.; Warburton, R. J.; Peace-Brewer, A. L.; Tussey, L. G.; Quinn, D. G.; McMichael, A. J.; Frelinger, Jeffrey A.

In: Journal of Immunology, Vol. 154, No. 3, 1995, p. 1088-1096.

Research output: Contribution to journalArticle

Matsui, M, Moots, RJ, Warburton, RJ, Peace-Brewer, AL, Tussey, LG, Quinn, DG, McMichael, AJ & Frelinger, JA 1995, 'Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition', Journal of Immunology, vol. 154, no. 3, pp. 1088-1096.
Matsui M, Moots RJ, Warburton RJ, Peace-Brewer AL, Tussey LG, Quinn DG et al. Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition. Journal of Immunology. 1995;154(3):1088-1096.
Matsui, M. ; Moots, R. J. ; Warburton, R. J. ; Peace-Brewer, A. L. ; Tussey, L. G. ; Quinn, D. G. ; McMichael, A. J. ; Frelinger, Jeffrey A. / Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition. In: Journal of Immunology. 1995 ; Vol. 154, No. 3. pp. 1088-1096.
@article{a3c84de121ad401e9c05fbf6293d28f2,
title = "Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition",
abstract = "During the course of extensive mutagenesis of HLA-A2.1, we examined influenza A matrix peptide (FMP)-specific CTL recognition of HMy2.C1R (C1R) cells expressing mutant HLA-A2.1 molecules, sensitized with synthetic peptide, FMP 58-66, (exogenous peptide), or infected with influenza A virus (endogenous peptide). Most mutants showed equivalent presentation of exogenous and endogenous peptides to FMP-specific CTL. However, five of the mutants differed in this property. Two of the five mutants, F9L and T134K, present exogenous peptide to FMP-specific CTL, but fail to present endogenous peptide to CTL. Western blot analysis using anti-matrix protein Ab indicates that the matrix protein is expressed in these mutants after infection with virus. Interestingly, transfection of these two mutants with a minigene encoding FMP 58-66 results in efficient lysis by FMP-specific CTL. Peptide- binding assays demonstrate that the two mutations dramatically decrease the binding of FMP. However, these mutants bind FMP as well as wild type in the presence of exogenously added human β2-m, suggesting that the lower affinity for β2-m leads to the inability to present endogenous peptide. The remaining three mutants, Y27N, Q32K, and S132C, fail to present exogenous peptide, but present endogenous peptide to FMP-specific CTL. Pulse-chase analyses followed by endoglycosidase-H treatment show that the rate of maturation and processing of the five mutant HLA-A2 molecules in C1R cells is identical to that of wild type. Overall, this study suggests that the assembly and subsequent recognition of endogenous peptide differs from that of exogenous peptide.",
author = "M. Matsui and Moots, {R. J.} and Warburton, {R. J.} and Peace-Brewer, {A. L.} and Tussey, {L. G.} and Quinn, {D. G.} and McMichael, {A. J.} and Frelinger, {Jeffrey A}",
year = "1995",
language = "English (US)",
volume = "154",
pages = "1088--1096",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition

AU - Matsui, M.

AU - Moots, R. J.

AU - Warburton, R. J.

AU - Peace-Brewer, A. L.

AU - Tussey, L. G.

AU - Quinn, D. G.

AU - McMichael, A. J.

AU - Frelinger, Jeffrey A

PY - 1995

Y1 - 1995

N2 - During the course of extensive mutagenesis of HLA-A2.1, we examined influenza A matrix peptide (FMP)-specific CTL recognition of HMy2.C1R (C1R) cells expressing mutant HLA-A2.1 molecules, sensitized with synthetic peptide, FMP 58-66, (exogenous peptide), or infected with influenza A virus (endogenous peptide). Most mutants showed equivalent presentation of exogenous and endogenous peptides to FMP-specific CTL. However, five of the mutants differed in this property. Two of the five mutants, F9L and T134K, present exogenous peptide to FMP-specific CTL, but fail to present endogenous peptide to CTL. Western blot analysis using anti-matrix protein Ab indicates that the matrix protein is expressed in these mutants after infection with virus. Interestingly, transfection of these two mutants with a minigene encoding FMP 58-66 results in efficient lysis by FMP-specific CTL. Peptide- binding assays demonstrate that the two mutations dramatically decrease the binding of FMP. However, these mutants bind FMP as well as wild type in the presence of exogenously added human β2-m, suggesting that the lower affinity for β2-m leads to the inability to present endogenous peptide. The remaining three mutants, Y27N, Q32K, and S132C, fail to present exogenous peptide, but present endogenous peptide to FMP-specific CTL. Pulse-chase analyses followed by endoglycosidase-H treatment show that the rate of maturation and processing of the five mutant HLA-A2 molecules in C1R cells is identical to that of wild type. Overall, this study suggests that the assembly and subsequent recognition of endogenous peptide differs from that of exogenous peptide.

AB - During the course of extensive mutagenesis of HLA-A2.1, we examined influenza A matrix peptide (FMP)-specific CTL recognition of HMy2.C1R (C1R) cells expressing mutant HLA-A2.1 molecules, sensitized with synthetic peptide, FMP 58-66, (exogenous peptide), or infected with influenza A virus (endogenous peptide). Most mutants showed equivalent presentation of exogenous and endogenous peptides to FMP-specific CTL. However, five of the mutants differed in this property. Two of the five mutants, F9L and T134K, present exogenous peptide to FMP-specific CTL, but fail to present endogenous peptide to CTL. Western blot analysis using anti-matrix protein Ab indicates that the matrix protein is expressed in these mutants after infection with virus. Interestingly, transfection of these two mutants with a minigene encoding FMP 58-66 results in efficient lysis by FMP-specific CTL. Peptide- binding assays demonstrate that the two mutations dramatically decrease the binding of FMP. However, these mutants bind FMP as well as wild type in the presence of exogenously added human β2-m, suggesting that the lower affinity for β2-m leads to the inability to present endogenous peptide. The remaining three mutants, Y27N, Q32K, and S132C, fail to present exogenous peptide, but present endogenous peptide to FMP-specific CTL. Pulse-chase analyses followed by endoglycosidase-H treatment show that the rate of maturation and processing of the five mutant HLA-A2 molecules in C1R cells is identical to that of wild type. Overall, this study suggests that the assembly and subsequent recognition of endogenous peptide differs from that of exogenous peptide.

UR - http://www.scopus.com/inward/record.url?scp=0028829904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028829904&partnerID=8YFLogxK

M3 - Article

C2 - 7822785

AN - SCOPUS:0028829904

VL - 154

SP - 1088

EP - 1096

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -